Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17235685 | 0.94 | IMPDH2 (0.35) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL15280219 | 0.92 | P2RY2 (0.39) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL17546719 | 0.92 | P2RY2 (0.39) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL18081896 | 0.91 | P2RY6 (0.35) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL17655049 | 0.90 | IMPDH2 (0.35) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL15765695 | 0.90 | IMPDH2 (0.35) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL15258090 | 0.89 | P2RY2 (0.36) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL18081881 | 0.89 | P2RY2 (0.36) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL15494174 | 0.89 | P2RY2 (0.36) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL17792581 | 0.89 | P2RY2 (0.36) | IMPDH2P2RY2P2RY4P2RY6TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289674-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | MODERNATX, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160024547-A1 | MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS | ARES CAPITAL CORPORATION, AS AGENT | 2016-01-28 | — | — | US | disclosed |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-09-03 | — | — | US | disclosed |
| US-20140275229-A1 | MODIFIED POLYNUCLEOTIDES ENCODING UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140255467-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140155474-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING CYSTIC FIBROSIS | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | IMPDH2 1669/4885P2RY2 3286/4885P2RY4 3464/4885 |
| US-20160289674-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | POLRMT, POLN, MSH2 | IMPDH2 1369/4885P2RY2 1489/4885P2RY4 1751/4885 |
| US-20140255467-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 | PABPC4, TRDMT1, MSH2 | IMPDH2 2167/4885P2RY2 4011/4885P2RY4 2392/4885 |
| US-20140155474-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING CYSTIC FIBROSIS | POLRMT, CFTR, POLN | IMPDH2 2344/4885P2RY2 845/4885P2RY4 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.